Skip to main content
Premium Trial:

Request an Annual Quote

Houston Investment Bank Closes $11M Life Science Fund

NEW YORK, Oct. 1 – Houston-based investment banking firm Sanders Morris Harris has closed its $11 million LifeSciences Opportunity Fund, which will look to invest in early- and middle-stage functional genomics and proteomics companies.

"Our first LifeSciences Fund is focused on investing in companies with technologies that have a high likelihood of playing a key role in commercializing new scientific discoveries arising from the recent historical developments in biomedical research such as the human genome project," James Gale, a managing director at the firm, said in a statement released Friday.

The fund, which will also look to invest in drug delivery and gene therapy technologies, is designed to give individual investors the chance to invest in emerging medical technology.

So far, the fund has made two investments. Sanders Morris Harris has over $3 billion under management. 

 

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.